Medivation, Orexigen Highlight Late-Stage Strategies for Closely-Watched Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Medivation will push on with Phase III trials despite an Alzheimer's failure, while Orexigen says a competitor's obesity drug could affect partnering plans.